LUNG-MAP SUB-STUDY, NCT06031688: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) |
|
|
| Recruiting | 2 | 56 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, Tepotinib, c-Met Inhibitor MSC2156119J, EMD 1214063, EMD-1214063, EMD1214063, MSC2156119J | SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, EMD Serono | Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | 05/28 | 05/29 | | |
NCT04507802: Helmet vs Face Mask in Patients With Acute Respiratory Distress Syndrome |
|
|
| Not yet recruiting | N/A | 60 | RoW | Non invasive ventilation via helmet | Hamad Medical Corporation | Acute Respiratory Distress Syndrome, Noninvasive Ventilation, Corona Virus Disease, Acute Respiratory Failure | 05/21 | 08/21 | | |
